open access

Vol 20, No 1 (2016)
REVIEV
Published online: 2016-03-31
Get Citation

Hypertension and beyond — does circulating irisin matter?

Aleksandra Taszarek, Anna Kaczmarkiewicz, Tomasz Miazgowski
DOI: 10.5603/AH.2016.0004
·
Arterial Hypertension 2016;20(1):16-20.

open access

Vol 20, No 1 (2016)
REVIEV
Published online: 2016-03-31

Abstract

Irisin is a myokine secreted by skeletal muscles. It has been proposed to drive the brown-fat-like conversion of the white adipose tissue. By enhancing energy expenditure, irisin may affect systemic metabolism and be associated with insulin resistance; however, the mechanism(s) of action still remain largely unexplained. The discovery of irisin can contribute to the exploration of the novel and effective therapeutic targets or therapeutic strategies of metabolic diseases or metabolism-associated health issues. In this review, based on the recent literature (from 2013 to 2015 inclusive), we will systematically discuss the associations of irisin with obesity, type 2 diabetes, lipid disorders, and hypertension. We also introduce unanswered questions for future research.

Abstract

Irisin is a myokine secreted by skeletal muscles. It has been proposed to drive the brown-fat-like conversion of the white adipose tissue. By enhancing energy expenditure, irisin may affect systemic metabolism and be associated with insulin resistance; however, the mechanism(s) of action still remain largely unexplained. The discovery of irisin can contribute to the exploration of the novel and effective therapeutic targets or therapeutic strategies of metabolic diseases or metabolism-associated health issues. In this review, based on the recent literature (from 2013 to 2015 inclusive), we will systematically discuss the associations of irisin with obesity, type 2 diabetes, lipid disorders, and hypertension. We also introduce unanswered questions for future research.

Get Citation

Keywords

irisin; hypertension; metabolic diseases; diabetes

About this article
Title

Hypertension and beyond — does circulating irisin matter?

Journal

Arterial Hypertension

Issue

Vol 20, No 1 (2016)

Pages

16-20

Published online

2016-03-31

DOI

10.5603/AH.2016.0004

Bibliographic record

Arterial Hypertension 2016;20(1):16-20.

Keywords

irisin
hypertension
metabolic diseases
diabetes

Authors

Aleksandra Taszarek
Anna Kaczmarkiewicz
Tomasz Miazgowski

References (52)
  1. Jedrychowski MP, Wrann CD, Paulo JA, et al. Detection and Quantitation of Circulating Human Irisin by Tandem Mass Spectrometry. Cell Metab. 2015; 22(4): 734–740.
  2. McMillan AC, White MD. Induction of thermogenesis in brown and beige adipose tissues: molecular markers, mild cold exposure and novel therapies. Curr Opin Endocrinol Diabetes Obes. 2015; 22(5): 347–352.
  3. Erickson HP. Irisin and FNDC5 in retrospect: An exercise hormone or a transmembrane receptor? Adipocyte. 2013; 2(4): 289–293.
  4. Norheim F, Langleite TM, Hjorth M, et al. The effects of acute and chronic exercise on PGC-1α, irisin and browning of subcutaneous adipose tissue in humans. FEBS J. 2014; 281(3): 739–749.
  5. Kraemer RR, Shockett P, Webb ND, et al. A transient elevated irisin blood concentration in response to prolonged, moderate aerobic exercise in young men and women. Horm Metab Res. 2014; 46(2): 150–154.
  6. Kurdiova T, Balaz M, Vician M, et al. Effects of obesity, diabetes and exercise on Fndc5 gene expression and irisin release in human skeletal muscle and adipose tissue: in vivo and in vitro studies. J Physiol. 2014; 592(5): 1091–1107.
  7. Moraes C, Leal VO, Marinho SM, et al. Resistance exercise training does not affect plasma irisin levels of hemodialysis patients. Horm Metab Res. 2013; 45(12): 900–904.
  8. Pekkala S, Wiklund PK, Hulmi JJ, et al. Are skeletal muscle FNDC5 gene expression and irisin release regulated by exercise and related to health? J Physiol. 2013; 591(21): 5393–5400.
  9. Hecksteden A, Wegmann M, Steffen A, et al. Irisin and exercise training in humans - results from a randomized controlled training trial. BMC Med. 2013; 11: 235.
  10. Kerstholt N, Ewert R, Nauck M, et al. Association of circulating irisin and cardiopulmonary exercise capacity in healthy volunteers: results of the Study of Health in Pomerania. BMC Pulm Med. 2015; 15: 41.
  11. Hew-Butler T, Landis-Piwowar K, Byrd G, et al. Plasma irisin in runners and nonrunners: no favorable metabolic associations in humans. Physiol Rep. 2015; 3(1).
  12. Chen Jq, Huang Yy, Gusdon AM, et al. Irisin: a new molecular marker and target in metabolic disorder. Lipids Health Dis. 2015; 14: 2.
  13. Saleem A, Safdar A, Haikalis M, et al. Exercise-induced amelioration of diet-induced obesity and diabetes is not regulated by irisin. FASEB J. 2015; 29(992): 4.
  14. Zhang W, Chang L, Zhang C, et al. Central and peripheral irisin differentially regulate blood pressure. Cardiovasc Drugs Ther. 2015; 29(2): 121–127.
  15. Yan B, Shi X, Zhang H, et al. Association of serum irisin with metabolic syndrome in obese Chinese adults. PLoS One. 2014; 9(4): e94235.
  16. Sesti G, Andreozzi F, Fiorentino TV, et al. High circulating irisin levels are associated with insulin resistance and vascular atherosclerosis in a cohort of nondiabetic adult subjects. Acta Diabetol. 2014; 51(5): 705–713.
  17. Brondani LA, Boelter G, Assmann TS, et al. Irisin-encoding gene (FNDC5) variant is associated with changes in blood pressure and lipid profile in type 2 diabetic women but not in men. Metabolism. 2015; 64(9): 952–957.
  18. Ebert T, Focke D, Petroff D, et al. Serum levels of the myokine irisin in relation to metabolic and renal function. Eur J Endocrinol. 2014; 170(4): 501–506.
  19. Park KH, Zaichenko L, Brinkoetter M, et al. Circulating irisin in relation to insulin resistance and the metabolic syndrome. J Clin Endocrinol Metab. 2013; 98(12): 4899–4907.
  20. Liu TY, Shi CX, Gao R, et al. Irisin inhibits hepatic gluconeogenesis and increases glycogen synthesis via the PI3K/Akt pathway in type 2 diabetic mice and hepatocytes. Clin Sci (Lond). 2015; 129(10): 839–850.
  21. Zhu Di, Wang H, Zhang J, et al. Irisin improves endothelial function in type 2 diabetes through reducing oxidative/nitrative stresses. J Mol Cell Cardiol. 2015; 87: 138–147.
  22. Xiong XQ, Chen D, Sun HJ, et al. FNDC5 overexpression and irisin ameliorate glucose/lipid metabolic derangements and enhance lipolysis in obesity. Biochim Biophys Acta. 2015; 1852(9): 1867–1875.
  23. Højlund K, Boström P. Irisin in obesity and type 2 diabetes. J Diabetes Complications. 2013; 27(4): 303–304.
  24. Vamvini MT, Aronis KN, Panagiotou G, et al. Irisin mRNA and circulating levels in relation to other myokines in healthy and morbidly obese humans. Eur J Endocrinol. 2013; 169(6): 829–834.
  25. Zhang HJ, Zhang XF, Ma ZM, et al. Irisin is inversely associated with intrahepatic triglyceride contents in obese adults. J Hepatol. 2013; 59(3): 557–562.
  26. Stengel A, Hofmann T, Goebel-Stengel M, et al. Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity--correlation with body mass index. Peptides. 2013; 39: 125–130.
  27. Pardo M, Crujeiras AB, Amil M, et al. Association of irisin with fat mass, resting energy expenditure, and daily activity in conditions of extreme body mass index. Int J Endocrinol. 2014; 2014: 857270.
  28. Huh JY, Panagiotou G, Mougios V, et al. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism. 2012; 61(12): 1725–1738.
  29. Crujeiras AB, Pardo M, Arturo RR, et al. Longitudinal variation of circulating irisin after an energy restriction-induced weight loss and following weight regain in obese men and women. Am J Hum Biol. 2014; 26(2): 198–207.
  30. Sanchis-Gomar F, Alis R, Pareja-Galeano H, et al. Circulating irisin levels are not correlated with BMI, age, and other biological parameters in obese and diabetic patients. Endocrine. 2014; 46(3): 674–677.
  31. Moreno-Navarrete JM, Ortega F, Serrano M, et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab. 2013; 98(4): E769–E778.
  32. Choi YK, Kim MK, Bae KH, et al. Serum irisin levels in new-onset type 2 diabetes. Diabetes Res Clin Pract. 2013; 100(1): 96–101.
  33. Chen Jq, Huang Yy, Gusdon AM, et al. Irisin: a new molecular marker and target in metabolic disorder. Lipids Health Dis. 2015; 14: 2.
  34. Crujeiras AB, Pardo M, Casanueva FF. Irisin: 'fat' or artefact. Clin Endocrinol (Oxf). 2015; 82(4): 467–474.
  35. Espes D, Lau J, Carlsson PO. Increased levels of irisin in people with long-standing Type 1 diabetes. Diabet Med. 2015; 32(9): 1172–1176.
  36. Xiang L, Xiang G, Yue L, et al. Circulating irisin levels are positively associated with endothelium-dependent vasodilation in newly diagnosed type 2 diabetic patients without clinical angiopathy. Atherosclerosis. 2014; 235(2): 328–333.
  37. Liu JJ, Wong MDS, Toy WC, et al. Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complications. 2013; 27(4): 365–369.
  38. Zhang M, Chen P, Chen S, et al. The association of new inflammatory markers with type 2 diabetes mellitus and macrovascular complications: a preliminary study. Eur Rev Med Pharmacol Sci. 2014; 18(11): 1567–1572.
  39. Duran ID, Gülçelik NE, Ünal M, et al. Irisin levels in the progression of diabetes in sedentary women. Clin Biochem. 2015; 48(18): 1268–1272.
  40. Assyov Y, Gateva A, Tsakova A, et al. Irisin in the Glucose Continuum. Exp Clin Endocrinol Diabetes. 2016; 124(1): 22–27.
  41. Yuksel MA, Oncul M, Tuten A, et al. Maternal serum and fetal cord blood irisin levels in gestational diabetes mellitus. Diabetes Res Clin Pract. 2014; 104(1): 171–175.
  42. Kuzmicki M, Telejko B, Lipinska D, et al. Serum irisin concentration in women with gestational diabetes. Gynecol Endocrinol. 2014; 30(9): 636–639.
  43. Wawrusiewicz-Kurylonek N, Telejko B, Kuzmicki M, et al. Increased Maternal and Cord Blood Betatrophin in Gestational Diabetes. PLoS One. 2015; 10(6): e0131171.
  44. Zhao L, Li J, Li ZL, et al. Circulating irisin is lower in gestational diabetes mellitus. Endocr J. 2015; 62(10): 921–926.
  45. Ebert T, Stepan H, Schrey S, et al. Serum levels of irisin in gestational diabetes mellitus during pregnancy and after delivery. Cytokine. 2014; 65(2): 153–158.
  46. Lopez-Legarrea P, de la Iglesia R, Crujeiras AB, et al. Higher baseline irisin concentrations are associated with greater reductions in glycemia and insulinemia after weight loss in obese subjects. Nutr Diabetes. 2014; 4: e110.
  47. Crujeiras AB, Zulet MA, Lopez-Legarrea P, et al. Association between circulating irisin levels and the promotion of insulin resistance during the weight maintenance period after a dietary weight-lowering program in obese patients. Metabolism. 2014; 63(4): 520–531.
  48. Tang S, Zhang R, Jiang F, et al. Circulating irisin levels are associated with lipid and uric acid metabolism in a Chinese population. Clin Exp Pharmacol Physiol. 2015 [Epub ahead of print].
  49. de la Iglesia R, Lopez-Legarrea P, Crujeiras AB, et al. Plasma irisin depletion under energy restriction is associated with improvements in lipid profile in metabolic syndrome patients. Clin Endocrinol (Oxf). 2014; 81(2): 306–311.
  50. Wen MS, Wang CY, Lin SL, et al. Decrease in irisin in patients with chronic kidney disease. PLoS One. 2013; 8(5): e64025.
  51. Panagiotou G, Mu L, Na B, et al. Circulating irisin, omentin-1, and lipoprotein subparticles in adults at higher cardiovascular risk. Metabolism. 2014; 63(10): 1265–1271.
  52. Emanuele E, Minoretti P, Pareja-Galeano H, et al. Serum irisin levels, precocious myocardial infarction, and healthy exceptional longevity. Am J Med. 2014; 127(9): 888–890.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl